Lastly let me finish up with inflammation, so despite availability of really good agents now for rheumatoid arthritis including methotrexate for upfront therapy and biologics for later lines of therapy, there's a still a big unmet need and if you look at the ACR 20 -- the ACR 70s in particular, they leave something to be desired in later lines of therapy. So, this is where we think the unmet need is, this is where we think the commercial opportunity is and this is where we're going. So, we in licensed, as you know Filgotinib from Galapagos, it's a selective JAK 1 inhibitor, once daily dosing, we have a huge safety data base, 900 patient years of clinical trial experience, which is very unusual after Phase 2 only and what we can say it is well tolerated. We didn’t see any changes in laboratory abnormalities particularly haemoglobin and lipids. Favourable of Phase 2 data on RA and Crohn's were reported and were currently in negotiation with regulatory authorities of starting Phase 3 studies in Rheumatoid Arthritis and Crohn's disease.
Just quickly there, Filgotinib is not the only JAK inhibitor, one of them Tofacitinib by Pfizer was approved in U.S. not in Europe, Baricitinib is close to filing or have filed an ABT-494 shown here is the -- even though it's difficult to do a cross study comparison. But as you see the ACR 20, 50s and 70s of Filgotinib compare very favourably with the competitive compounds and we are very excited about moving this forward. And then lastly, we have a compound the antibody 5745 in clinical development for ulcerative colitis shown here is the Phase 2 data that were reported, this shows various doses of GS-5745 versus placebo and as you see that the response in the active is much improved over placebo. So Phase 3 study in ulcerative colitis is ongoing, we are also looking at the same compound for Crohn's and RA and CLPD.